Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice

OBJECTIVE: A prophylactic vaccine is needed to control the HCV epidemic, with genotypes 1–3 causing >80% of worldwide infections. Vaccine development is hampered by HCV heterogeneity, viral escape including protection of conserved neutralising epitopes and suboptimal efficacy of HCV cell culture...

Descripción completa

Detalles Bibliográficos
Autores principales: Alzua, Garazi Pena, Pihl, Anne Finne, Offersgaard, Anna, Duarte Hernandez, Carlos Rene, Duan, Zhe, Feng, Shan, Fahnøe, Ulrik, Sølund, Christina, Weis, Nina, Law, Mansun, Prentoe, Jannick C, Christensen, Jan Pravsgaard, Bukh, Jens, Gottwein, Judith Margarete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933178/
https://www.ncbi.nlm.nih.gov/pubmed/35918103
http://dx.doi.org/10.1136/gutjnl-2021-326323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933178/
https://www.ncbi.nlm.nih.gov/pubmed/35918103
http://dx.doi.org/10.1136/gutjnl-2021-326323

Ejemplares similares